At 9:30 a.m. on March 15, with the sound of a gong in the Shanghai Stock Exchange, Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (stock abbreviation: Cheng Yi Pharmaceutical, stock code: 603811) was officially listed on the main board, becoming the first main board listed enterprise in Dongtou District, Wenzhou, which is also the 20th listed enterprise in Wenzhou.
On the first day of trading, Cheng Yi Pharmaceutical performed well in the securities market, opening at an offering price of 15.76 yuan, quickly reaching the upper limit of its first day of trading increase of 43.97%, with a stock price of 22.69 yuan. According to this calculation, the total market value of Cheng Yi Pharmaceutical has reached 1.933 billion yuan.
Cheng Yi Pharmaceutical is a "Shinise" pharmaceutical enterprise with a history of 50 years, specializing in the production of pharmaceutical injections, capsules, APIs, etc. At first, it was a small workshop style military family factory in Dongtou District, Wenzhou. Since 1980, the business efficiency of the enterprise has continued to grow without loss. It has successively won the honors of national contract abiding and trustworthy unit, national high-tech enterprise, green enterprise in Zhejiang Province, etc. The "Lishan" trademark and "Sankang" trademark under the company have been successively awarded as famous trademarks in Zhejiang Province. In recent years, the company has developed rapidly and has become one of the top 500 companies in China's pharmaceutical industry with total profits as legal entities.
It is reported that Cheng Yi Pharmaceutical has issued 21.3 million new shares, with a total share capital of 85.2 million shares after the issuance. The raised investment funds will be used for the technical renovation project of the preparation building, the construction project of the R&D center, and the marketing network construction project.
The chairman of the company, Yan Yiyi, stated that after going public, the company will adhere to innovation as the driving force, talent as the foundation, and market orientation, accelerate product upgrading and upgrading, and promote the transformation of product structure from raw materials to formulations. Among them, the leading products will transform into marine products, and the company will be built into a drug production base led by marine pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine. By integrating various resources such as technology, market, talent, and capital, we strive to become a leading enterprise in the industry.
At the same time, the company will strictly follow the requirements of the listing rules, maintain transparency and a good operational structure, and leverage the power of the capital market to achieve another takeoff in the fields of marine pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine.
It is reported that listing provides greater space and abundant funds for the development of Cheng Yi Pharmaceutical. Next, the company will increase its research and development of new drugs, investing at least 210 million yuan in new drug development and production process technology transformation during the 13th Five Year Plan period, so that the company's business will shift from raw material drugs to formulations.
Focused on pharmaceutical manufacturing and sales for 50 years
The predecessor of Cheng Yi Pharmaceutical was first founded in 1966. The company is specialized in the R&D, production and sales of drugs. The therapeutic effects of its products cover arthritis, diuresis, sedation and brain tonic, anti-virus and anti-tumor, etc. The main products include Glucosamine hydrochloride preparations and APIs, tolasemide preparations, Gastrodin APIs, Ribavirin and Azathioprine APIs. Among them, Glucosamine hydrochloride preparations and APIs, tolasemide preparations and Gastrodin APIs mainly focus on the domestic market, Ribavirin and Azathioprine APIs are mainly exported, and the products are currently exported to the United States, Canada, Europe, South Africa, Southeast Asia and more than 20 countries and regions.
According to the announcement, Cheng Yi Pharmaceutical and its subsidiaries have 65 drug production approval numbers. Among them, 43 drug regulations were listed in the national medical insurance catalogue (including 31 Class A and 12 Class B drug regulations), 15 drugs were listed in the National Essential medicines Catalogue (2012), and 31 product regulations were produced throughout the year. As of the signing date of this prospectus, the company has 4 national new drug varieties, including 3 Class II new drugs and 1 Class IV new drug; Has 9 invention patents and 3 utility model patents.
Top 500 Legal Entity Profits of National Pharmaceutical Industry Enterprises
The company has passed national GMP certification, international standard ISO9001 (quality system), and ISO14001 (environmental system) certification. Since 1998, the company has continuously passed the GMP audit of TGA in Australia; In September 2010, the company successfully passed an international GMP joint audit conducted by Australia's TGA, the US FDA, the EU's EMEA, and Singapore's HAS (as observers); In February 2014, the company passed an on-site GMP audit by the German drug regulatory department; In August 2014, the company passed an on-site audit by the US FDA. In June 2015, the company passed the national new version of GMP certification. The company's main export products have registered DMF documents and CEP certificates in the US and EU regulatory markets. The company has become an important raw material drug supplier in the global pharmaceutical industry.
The enterprise is a national contract abiding and trustworthy unit, a national key high-tech enterprise, a high-tech enterprise in Zhejiang Province, and a green enterprise in Zhejiang Province; Multiple products have been awarded titles such as branded products, high-quality pharmaceutical products, and high-quality products; The company's "Lishan" trademark and "Sankang" trademark have been rated as famous trademarks in Zhejiang Province. In recent years, the company has developed rapidly and has become one of the top 500 profit companies in China's pharmaceutical industry.
The chairman has received multiple honors
Mr. Yan Yiyi, the controlling shareholder and actual controller of Cheng Yi Pharmaceutical, directly holds 25.05 million shares of the company, accounting for 39.20% of the total share capital before the issuance.
Mr. Yan Yiyi was born in 1949, Chinese nationality, without overseas Permanent residency, junior college degree, senior manager. Formerly served as the director of Tongshan Pharmaceutical Factory in Dongtou County, the director of Wenzhou Third Pharmaceutical Factory, the chairman and general manager of Zheng Cheng Yi Pharmaceutical Co., Ltd., and the executive director and general manager of Wenzhou Third Pharmaceutical Import and Export; He is currently the chairman of Zhejiang Cheng Yi Pharmaceutical Co., Ltd., the executive director of Jiangsu Cheng Yi Pharmaceutical Co., Ltd., the chairman of Wenzhou Dongtou District Cheng Yi Microfinance Co., Ltd., and the chairman of Wenzhou Lixiang Animal Experimental Research Institute.
Mr. Yan Yiyi has been awarded many honorary titles, including Outstanding Entrepreneur of Small and Medium Enterprises in Zhejiang Province in 2011, Outstanding Entrepreneur of Wenzhou City in 2013, Meritorious Entrepreneur of Wenzhou City in 2014, and Outstanding Entrepreneur of Wenzhou City in 2015.
(Comprehensive Securities Daily)